Loading
Life sciences · Journal article
Cancer Immunology Research · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Early-onset colorectal cancer (EOCRC), typically defined as colorectal cancer diagnosed before 50 years of age, is increasing in incidence worldwide and exhibits distinctive clinical, molecular, and environmental features compared with later-onset (LOCRC) disease. However, the tumor-immune microenvironment (TiME) of EOCRC and its implications for prevention and therapy remain poorly characterized. In this review, we synthesize current evidence on the TiME of EOCRC and contrast it with that of conventional LOCRC. We first discuss global features of the EOCRC immune landscape, including innate and adaptive immune composition, functional states, and spatial organization, highlighting areas where apparent age-related differences reflect true biology versus confounding by tumor site, stage, or mismatch repair (MMR) status. We then examine immunogenomic and epigenomic determinants-such as MMR deficiency distribution, microbial mutational signatures, chromosomal instability, and age-conditioned methylation programs-that shape neoantigen landscapes, antigen presentation, and immune evasion in younger patients. Next, we review microbiome-driven immunomodulation, focusing on dysbiosis, genotoxic bacteria, and early-life and young-adult exposures as joint modifiers of mucosal immunity and tumor development. Finally, we explore how these insights inform immune-based prevention (risk stratification, screening, diet and microbiome interventions, and chemoprevention) and immunotherapy strategies, including checkpoint blockade and rational combinations in the predominant microsatellite-stable EOCRC population.